


Ilunocitinib

Cat. No.:	HY-132819		
CAS No.:	1187594-14-4		
Molecular Formula:	C ₁₇ H ₁₇ N ₇ O ₂ S		
Molecular Weight:	383.43		
Target:	JAK		
Pathway:	Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (652.01 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.6080 mL	13.0402 mL	26.0804 mL
	5 mM	0.5216 mL	2.6080 mL	5.2161 mL
	10 mM	0.2608 mL	1.3040 mL	2.6080 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (5.42 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (5.42 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.42 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Ilunocitinib (compound 27) is a JAK inhibitor (extracted from patent WO2009114512A1)^[1].

REFERENCES

[1]. James D. Rodgers, et al. Azetidine and cyclobutane derivatives as jak inhibitors. Patent. WO2009114512A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA